Prestige Consumer Healthcare (PBH) EBIT Margin (2010 - 2025)
Prestige Consumer Healthcare (PBH) recorded quarterly EBIT Margin of 29.1% in Q4 2025, little changed quarter-over-quarter from 29.06% in Q3 2025, and down 257.0% on a YoY basis from 18.54% in Q4 2024.
Prestige Consumer Healthcare (PBH) EBIT Margin (2010 - 2025) Analysis & Trends
Prestige Consumer Healthcare's EBIT Margin history runs 16 years deep, the most recent figure standing at 29.1% for Q4 2025.
- In Q4 2025, EBIT Margin fell 257.0% year-over-year to 29.1%; the TTM figure through Dec 2025 stood at 29.21% (down 35.0% YoY), while the FY2025 annual figure was 29.6%, down 83.0% from the prior year.
- EBIT Margin was 29.1% for Q4 2025 at Prestige Consumer Healthcare, roughly flat from 29.06% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 33.93% in Q2 2021 to a low of 98.3% in Q1 2023.
- Historically, EBIT Margin has averaged 23.6% across 5 years, with a median of 29.77% in 2024.
- The sharpest annual moves came in 2023 and 2024: EBIT Margin sank 12730 bps in 2023, then jumped 12795 bps in 2024.
- A 5-year view of EBIT Margin shows it stood at 30.09% in 2021, then climbed by 5 bps to 31.64% in 2022, then fell by 3 bps to 30.71% in 2023, then gained by 3 bps to 31.68% in 2024, then slipped by 8 bps to 29.1% in 2025.
- The last three EBIT Margin figures came in at 29.1% (Q4 2025), 29.06% (Q3 2025), and 28.76% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 16.37% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 36.83% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 41.69% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 20.77% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 23.74% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 22.39% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -122.23% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -12.88% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 21.55% |
| 10 | Prestige Consumer Healthcare | 2.37 Bn | 2.31 Bn | 157.37 Mn | 29.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 29.10% |
| Sep 30, 2025 | 29.06% |
| Jun 30, 2025 | 28.76% |
| Mar 31, 2025 | 29.82% |
| Dec 31, 2024 | 31.68% |
| Sep 30, 2024 | 29.72% |
| Jun 30, 2024 | 26.97% |
| Mar 31, 2024 | 29.66% |
| Dec 31, 2023 | 30.71% |
| Sep 30, 2023 | 30.82% |
| Jun 30, 2023 | 30.50% |
| Mar 31, 2023 | -98.30% |
| Dec 31, 2022 | 31.64% |
| Sep 30, 2022 | 29.17% |
| Jun 30, 2022 | 31.41% |
| Mar 31, 2022 | 29.01% |
| Dec 31, 2021 | 30.09% |
| Sep 30, 2021 | 28.44% |
| Jun 30, 2021 | 33.93% |
| Mar 31, 2021 | 29.84% |